Investigators sought to determine whether weight-based dosing of pembrolizumab could produce outcomes similar to standard fixed dosing for patients with NSCLC.

Pembro, made by pharma giant MSD, is hailed as a drug that saves and prolongs lives but it comes at an exorbitant cost ...

We conducted a retrospective cohort study of 414 patients with advanced NSCLC treated with pembrolizumab at a single center between 2016 and 2021. Patients received either fixed-dose or weight-based ...

Foundayo is now available for adult patients with obesity and weight-related comorbidities to reduce excess body weight and maintain reduction.

Current GLP-1 standards of care focus on once-weekly dosing, with doctor-recommended, supervised titration depending on ...

How Merck keeps the price of its lifesaving cancer drug, Keytruda, sky-high, locking out patients and squeezing health care ...

The U.S. Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection. The 7.2 mg dosage, called Wegovy HD, is intended for weight loss and long ...

A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

Federal regulators have approved the GLP-1 tablet Foundayo for weight loss. The once-daily oral pill provides an alternative ...

16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults The Phase 1 Part 3 trial will enroll a total of 40 obese, otherwise ...

Adults with overweight or obesity taking the new generation of weight loss drugs semaglutide and tirzepatide tend to eat ...